Our evidence that an EGFR–RAS–ERK–ZEB1 axis may contribute to the early stages of lung fibrosis suggests that inhibiting EGFR signalling may be of clinical relevance for regulating human fibrotic lung disease. This evidence concerns the gene ZEB1 and lung disorder.